Browsing Tag
BTK inhibitor
9 posts
Eli Lilly’s Jaypirca outpaces Imbruvica in landmark CLL head‑to‑head trial
Eli Lilly’s Jaypirca beats Imbruvica in a head-to-head CLL trial. Explore why this breakthrough matters for BTK therapy and cancer care.
Everest Medicines’ EVER001 shows promising Phase 1b/2a trial results for autoimmune kidney disease treatment
Everest Medicines has announced promising preliminary results from its ongoing Phase 1b/2a clinical trial of EVER001, a next-generation…
BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S.…
Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly’s oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive…
Lilly gets Jaypirca FDA approval for mantle cell lymphoma
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US…
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA…
Sanofi to acquire US biopharma company Principia Biopharma for $3.7bn
Sanofi acquisition of Principia Biopharma : French pharma giant Sanofi has signed an all-cash deal worth $3.68 billion…
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL
Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of…
FDA grants accelerated approval to AstraZeneca’s Calquence for mantle cell lymphoma treatment
AstraZeneca has achieved a significant milestone with the early FDA approval of Calquence (acalabrutinib) for the treatment of…